Clinical Trial Goal
To find out if tocilizumab is safe and works well to treat acute chest syndrome in SCD
You may be able to join this trial if you:
- Are 18 years old or older
- Have SCD
- Have not been treated with a BTK inhibitor like acalabrutinib, ibrutinib or zanubrutinib. Your doctor can tell you this
- Have not been treated with a JAK2 inhibitor like baricitinib, ruxolitinib, tofacitinib or upadacitinib. Your doctor can tell you this
- Have not been treated with an immunosuppressant or monoclonal antibody (name ending in -mab) in the last 6 months. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Tocilizumab is a monoclonal antibody that blocks IL-6 on certain cells.
You’ll get:
You’ll get:
- Tocilizumab– Given as intravenous (IV) infusion 1 time within 2 days of acute chest syndrome diagnosis
The clinical trial doctors will check your health for up to 3 months.
The Food and Drug Administration (FDA) has approved tocilizumab as an immunosuppressant. Using it to treat recently diagnosed acute chest syndrome is new and unproven.
Contacts
Austin Wesevich, MD, 773-834-6732, austin.wesevich@uchicagomedicine.org
Gabrielle Lapping-Carr, MD, 773-702-6808, glappingcarr@uchicago.edu
Locations
University of ChicagoRECRUITING
Chicago, Illinois
Austin Wesevich, MD, 773-834-6732, austin.wesevich@uchicagomedicine.org
Sponsors
lead: University of Chicago
